Grant: Undergraduate: Summer Studentship Award - Institute Community Support
University of Toronto
$5,000.00
V-ATPase "a" subunit/phospholipid interactions: a novel therapeutic target for preventing bone-loss in inflammatory arthritis
FY 2018-19
Summary
Current therapies to prevent pathological bone loss resulting from arthritis and osteoporosis lack effectiveness and have serious side effects. Osteoclasts normally dissolve bone by pumping acid onto the bone surface as part of a continuous renewal process, but this is accelerated in pathological bone loss. V-ATPase molecules are the acid pumps of osteoclasts, and inhibiting V-ATPase activity prevents bone loss in the laboratory, but compounds that reduce V-ATPase function also interfere with their essential activity in other parts of the body and are toxic. V-ATPases consist of many subunits, some having different isoforms. The distribution of isoforms varies, depending on the V-ATPase's final destination. One such isoform, a3, is found primarily in the osteoclast plasma membrane where it is responsible for pumping the acid onto bone. We have preliminary evidence that the N-terminal half of a3 targets the rest of the acid pump to the plasma membrane. Our goal is to understand exactly how a3 brings the pump to the osteoclast plasma membrane then use this protein/lipid interaction to screen for compounds that disrupt this interaction and thereby potentially 'knock down' the osteoclast VATPase without affecting other essential V-ATPases. Here we propose that Brooke Aspen assess the phosphoinositides (PIP) specificity of the a3 N-terminus in vitro using a protein-lipid overlay assay with a lipid array containing concentration gradients of common PIPs, towards the development of antiresorptive drugs that would only affect the osteoclast V-ATPase involved in pathological bone loss in inflammatory arthritis and osteoporosis
Department
Program
Undergraduate: Summer Studentship Award - Institute Community Support
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
400275
Name
Aspen Brooke
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Summer Studentships in Musculoskeletal Health
Projecttitle
V-ATPase "a" subunit/phospholipid interactions: a novel therapeutic target for preventing bone-loss in inflammatory arthritis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$5,000
Cihrequipment2
$0
Programname2
Undergraduate: Summer Studentship Award - Institute Community Support
Keyworddelim
Arthritis; Bone; Bone Loss; Bone Resorption; Osteoporosis; Skin
Abstract
Current therapies to prevent pathological bone loss resulting from arthritis and osteoporosis lack effectiveness and have serious side effects. Osteoclasts normally dissolve bone by pumping acid onto the bone surface as part of a continuous renewal process, but this is accelerated in pathological bone loss. V-ATPase molecules are the acid pumps of osteoclasts, and inhibiting V-ATPase activity prevents bone loss in the laboratory, but compounds that reduce V-ATPase function also interfere with their essential activity in other parts of the body and are toxic. V-ATPases consist of many subunits, some having different isoforms. The distribution of isoforms varies, depending on the V-ATPase's final destination. One such isoform, a3, is found primarily in the osteoclast plasma membrane where it is responsible for pumping the acid onto bone. We have preliminary evidence that the N-terminal half of a3 targets the rest of the acid pump to the plasma membrane. Our goal is to understand exactly how a3 brings the pump to the osteoclast plasma membrane then use this protein/lipid interaction to screen for compounds that disrupt this interaction and thereby potentially 'knock down' the osteoclast VATPase without affecting other essential V-ATPases. Here we propose that Brooke Aspen assess the phosphoinositides (PIP) specificity of the a3 N-terminus in vitro using a protein-lipid overlay assay with a lipid array containing concentration gradients of common PIPs, towards the development of antiresorptive drugs that would only affect the osteoclast V-ATPase involved in pathological bone loss in inflammatory arthritis and osteoporosis
Competitiondate
201901
Approvedterm2
0 yr 4 mths
Pinamesdelim
Aspen, Brooke
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $5,000~ $0~